RATIONALE AND OBJECTIVE: The aims of this study were to examine the differences between 32 opioid-dependent users treated with a very low dose of methadone or undergoing methadone-free abstinence and 32 controls. METHODS: SPECT analysis using [(99m)Tc] TRODAT-1 to assess striatal dopamine transporter (DAT) availability and [(123)I] ADAM to assess midbrain serotonin transporter (SERT) availability were performed. RESULTS: Lower striatal DAT and midbrain SERT availabilities were noted in low-dose methadone users. History of metamphatamine use was associated with the lower striatal DAT. The striatal DAT of methadone-free abstainers was also lower than controls. The midbrain SERT availability tended to be higher in the methadone-free abstainers than the low-dose methadone users. The severity of depressive symptoms was negatively correlated with midbrain SERT availability in the opioid users. CONCLUSION: The availability of striatal DAT tended to be, and the availability of midbrain SERT was, lower in the opioid users. History of metamphatamine use may confound the difference in straital DAT between controls and opioid users, as midbrain SERT and depressive symptoms are also associated with opioid use and abstinence.
RATIONALE AND OBJECTIVE: The aims of this study were to examine the differences between 32 opioid-dependent users treated with a very low dose of methadone or undergoing methadone-free abstinence and 32 controls. METHODS: SPECT analysis using [(99m)Tc] TRODAT-1 to assess striatal dopamine transporter (DAT) availability and [(123)I] ADAM to assess midbrain serotonin transporter (SERT) availability were performed. RESULTS: Lower striatal DAT and midbrain SERT availabilities were noted in low-dose methadone users. History of metamphatamine use was associated with the lower striatal DAT. The striatal DAT of methadone-free abstainers was also lower than controls. The midbrain SERT availability tended to be higher in the methadone-free abstainers than the low-dose methadone users. The severity of depressive symptoms was negatively correlated with midbrain SERT availability in the opioid users. CONCLUSION: The availability of striatal DAT tended to be, and the availability of midbrain SERT was, lower in the opioid users. History of metamphatamine use may confound the difference in straital DAT between controls and opioid users, as midbrain SERT and depressive symptoms are also associated with opioid use and abstinence.
Authors: Dean F Wong; Hiroto Kuwabara; David J Schretlen; Katherine R Bonson; Yun Zhou; Ayon Nandi; James R Brasić; Alane S Kimes; Marika A Maris; Anil Kumar; Carlo Contoreggi; Jonathan Links; Monique Ernst; Olivier Rousset; Stephen Zukin; Anthony A Grace; Jae Sung Lee; Charles Rohde; Donald R Jasinski; Albert Gjedde; Edythe D London Journal: Neuropsychopharmacology Date: 2006-09-13 Impact factor: 7.853
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong Journal: J Neurosci Date: 2006-06-14 Impact factor: 6.167
Authors: Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach Journal: Nat Neurosci Date: 2006-07-09 Impact factor: 24.884
Authors: N D Volkow; G J Wang; J S Fowler; S J Gatley; Y S Ding; J Logan; S L Dewey; R Hitzemann; J Lieberman Journal: Proc Natl Acad Sci U S A Date: 1996-09-17 Impact factor: 11.205
Authors: R T Malison; S E Best; C H van Dyck; E F McCance; E A Wallace; M Laruelle; R M Baldwin; J P Seibyl; L H Price; T R Kosten; R B Innis Journal: Am J Psychiatry Date: 1998-06 Impact factor: 18.112
Authors: Ke Xu; Dirk Lichtermann; Robert H Lipsky; Petra Franke; Xiehe Liu; Ying Hu; Liping Cao; Sibylle G Schwab; Dieter B Wildenauer; Claiton H D Bau; Erica Ferro; Will Astor; Thembi Finch; Jeanietta Terry; Julie Taubman; Wolfgang Maier; David Goldman Journal: Arch Gen Psychiatry Date: 2004-06
Authors: G H Tjon; T J De Vries; E Ronken; F Hogenboom; G Wardeh; A H Mulder; A N Schoffelmeer Journal: Eur J Pharmacol Date: 1994-02-03 Impact factor: 4.432
Authors: Felicia Kamp; Lisa Proebstl; Nora Penzel; Kristina Adorjan; Andrej Ilankovic; Oliver Pogarell; Gabi Koller; Michael Soyka; Peter Falkai; Nikolaos Koutsouleris; Joseph Kambeitz Journal: Neuropsychopharmacology Date: 2018-08-27 Impact factor: 7.853
Authors: Richard C Crist; James Li; Glenn A Doyle; Alex Gilbert; Bryan M Dechairo; Wade H Berrettini Journal: Am J Drug Alcohol Abuse Date: 2018-01-15 Impact factor: 3.829
Authors: Che Yu Kuo; Kao Chin Chen; I Hui Lee; Huai-Hsuan Tseng; Nan Tsing Chiu; Po See Chen; Yen Kuang Yang; Wei Hung Chang Journal: Clin Psychopharmacol Neurosci Date: 2022-05-31 Impact factor: 3.731
Authors: Eline R Zaaijer; Lonneke van Dijk; Kora de Bruin; Anna E Goudriaan; Laureen A Lammers; Maarten W J Koeter; Wim van den Brink; Jan Booij Journal: Psychopharmacology (Berl) Date: 2015-03-12 Impact factor: 4.530